New kinasinib! Intense two-target formula kills cancer – Dead!
This article was originally published in Scrip
Executive Summary
The prospects of kinase inhibitors have been boosted by new research suggesting that by tweaking present treatment regimens, these drugs could further extend cancer survival beyond three to six months. With high doses of kinase inhibitors, a second, cytotoxic mechanism of action becomes apparent, with preclinical studies indicating enhanced cancer cell killing. With some 25 kinase inhibitors on the market and another 400 somewhere in development, the findings might buff up the commercial future of a whole important cancer drug class without additional huge clinical outlay.